These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 4216151)

  • 1. [Blood changes in hyperthermic perfusion with chemotherapeutic preparations].
    Voronko EA; Fradkin SZ
    Vopr Onkol; 1974; 20(1):98. PubMed ID: 4216151
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinico-electrocardiographic changes during perfusion chemotherapy of malignant tumors of the extremities].
    Levin AO; Volodkovich HG
    Vopr Onkol; 1970; 16(8):3-7. PubMed ID: 4993603
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.
    Zwaveling JH; Maring JK; Mulder AB; Bom VJ; van Ginkel RJ; Schraffordt Koops H; Girbes AR; Hoekstra HJ; van der Meer J
    Cancer Res; 1996 Sep; 56(17):3948-53. PubMed ID: 8752162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
    Lejeune FJ; Eggermont AM
    J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
    [No Abstract]   [Full Text] [Related]  

  • 5. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study.
    Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma.
    Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H
    Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive evaluation of peripheral vasculature following regional hyperthermic chemotherapeutic perfusion (RHCP).
    Muchmore JH; Krementz ET; Kerstein MD
    Am Surg; 1987 Feb; 53(2):94-6. PubMed ID: 3544990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Soft tissue sarcoma: isolated hyperthermic extremity perfusion. Technique and indications].
    Schlag PM; Kettelhack C
    Chirurg; 1993 Jun; 64(6):455-60. PubMed ID: 8359057
    [No Abstract]   [Full Text] [Related]  

  • 9. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated regional limb hyperthermic perfusion as treatment for melanoma.
    Loescher LJ; Leigh S
    Cancer Nurs; 1984 Dec; 7(6):461-7. PubMed ID: 6568866
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined treatment of malignant tumors of the extremities. Regional perfusion chemotherapy].
    Kolessov VI; Levin AO
    Minerva Med; 1970 Sep; 61(71):3673-5. PubMed ID: 4989391
    [No Abstract]   [Full Text] [Related]  

  • 14. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma.
    Thompson JF; Lai DT; Ingvar C; Kam PC
    Melanoma Res; 1994 Mar; 4 Suppl 1():45-50. PubMed ID: 8038596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The state of hemopoiesis in the regional perfusion of malignant tumors of the extremities with sarcolysin, thio-TEPA and cyclophosphane].
    Levin AO; Babinina VF
    Vopr Onkol; 1967; 13(2):48-54. PubMed ID: 4971006
    [No Abstract]   [Full Text] [Related]  

  • 16. [On the method of hyperthermic chemotherapy by regional isolated perfusion for tumors of lower extremities].
    Xu SW; Chen F; Chao YH
    Zhonghua Zhong Liu Za Zhi; 1994 Jul; 16(4):310-3. PubMed ID: 7805565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal procedure for thermal delivery in hyperthermic/chemotherapeutic treatments in the isolated perfusion of the the limbs.
    Pace M; Millanta L; Polignano M; Gattai R; Macera Mascitelli E
    J Exp Clin Cancer Res; 2005 Mar; 24(1):35-42. PubMed ID: 15943029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective therapy: repeat limb perfusion for recurrent melanoma.
    Krementz ET
    J Am Coll Surg; 1996 Jun; 182(6):547-8. PubMed ID: 8646356
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of isolated limb perfusion to manage recurrent malignant melanoma.
    Ma D; Ariyan S
    Clin Plast Surg; 2000 Jul; 27(3):441-50, ix. PubMed ID: 10941564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients.
    Knorr C; Meyer T; Janssen T; Goehl J; Hohenberger W
    Eur J Surg Oncol; 2006 Mar; 32(2):224-7. PubMed ID: 16289716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.